# Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma

> **NCT02482454** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **The First People's Hospital of Changzhou** · enrollment: 50 (actual)

## Conditions studied

- Cholangiocarcinoma

## Interventions

- **PROCEDURE:** Radiofrequency ablation
- **BIOLOGICAL:** Cytokine-induced killer cells

## Key facts

- **NCT ID:** NCT02482454
- **Lead sponsor:** The First People's Hospital of Changzhou
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2012-07
- **Primary completion:** 2030-07
- **Final completion:** 2033-07
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2017-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02482454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02482454, "Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02482454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*